Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASPECT: Accuracy of 68Ga-Pentixafor PET/CT for Imaging Cardiac Sarcoidosis
2025-523646-27-00Phase 2Authorised
- Sponsor
- Erasmus MC
- Start
- Feb 2026
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pentixafor in cardiac sarcoidosis (CS) and sarcoidosis, sponsored by Erasmus MC. Primary endpoint: Sensitivity and specificity of 68Ga-Pentixafor PET/CT for cardiac sarcoidosis. Planned start Feb 2026; status: authorised.
02
Drugs
pentixafor
03
Conditions
cardiac sarcoidosis (CS)sarcoidosis
Beyond the preview
Go deeper on 2025-523646-27-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-523646-27-00.